Cargando…

Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice

INTRODUCTION: Malaria transmission blocking vaccines (TBV) are innovative approaches that aim to induce immunity in humans against Plasmodium during mosquito stage, neutralizing the capacity of the infected vectors to transmit malaria. Pfs230D1-EPA/Alhydrogel®, a promising protein-protein conjugate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coelho, Camila H., Gazzinelli-Guimaraes, Pedro Henrique, Howard, Jennifer, Barnafo, Emma, Alani, Nada A.H., Muratova, Olga, McCormack, Ashley, Kelnhofer, Emily, Urban, Joseph F., Narum, David L., Anderson, Charles, Langhorne, Jean, Nutman, Thomas B., Duffy, Patrick E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382667/ https://www.ncbi.nlm.nih.gov/pubmed/30685251 http://dx.doi.org/10.1016/j.vaccine.2019.01.027

Ejemplares similares

Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission
por: Rausch, Kelly M., et al.
Publicado: (2023)

Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins
por: Singh, Kavita, et al.
Publicado: (2020)

Safety and Immunogenicity of Pfs25-EPA/Alhydrogel(®), a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults
por: Talaat, Kawsar R., et al.
Publicado: (2016)

Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230
por: Scaria, Puthupparampil V., et al.
Publicado: (2019)

Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice
por: Healy, Sara A., et al.
Publicado: (2021)

The Pfs230 N-terminal fragment, Pfs230D1+: expression and characterization of a potential malaria transmission-blocking vaccine candidate
por: Lee, Shwu-Maan, et al.
Publicado: (2019)

Nanobodies against Pfs230 block Plasmodium falciparum transmission
por: Dietrich, Melanie H., et al.
Publicado: (2022)

Structural and immunological differences in Plasmodium falciparum sexual stage transmission-blocking vaccines comprised of Pfs25-EPA nanoparticles
por: MacDonald, Nicholas J., et al.
Publicado: (2023)

Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine
por: Singh, Susheel K., et al.
Publicado: (2021)

Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages
por: Huang, Wei-Chiao, et al.
Publicado: (2022)

Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose
por: Huang, Wei-Chiao, et al.
Publicado: (2020)

Development and Qualification of an Antigen Integrity Assay for a Plasmodium falciparum Malaria Transmission Blocking Vaccine Candidate, Pfs230
por: Miura, Kazutoyo, et al.
Publicado: (2022)

Helminth parasites and immune regulation
por: Gazzinelli-Guimaraes, Pedro H., et al.
Publicado: (2018)

Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum
por: Singh, Susheel K., et al.
Publicado: (2019)

Rare Alleles and Signatures of Selection on the Immunodominant Domains of Pfs230 and Pfs48/45 in Malaria Parasites From Western Kenya
por: Ochwedo, Kevin O., et al.
Publicado: (2022)

Identification of domains within Pfs230 that elicit transmission blocking antibody responses
por: Tachibana, Mayumi, et al.
Publicado: (2019)

Expression and purification optimization of an N-terminal Pfs230 transmission-blocking vaccine candidate
por: Lee, Shwu-Maan, et al.
Publicado: (2019)

Naturally Acquired Antibody Response to Malaria Transmission Blocking Vaccine Candidate Pvs230 Domain 1
por: Tentokam, Bergeline C. Nguemwo, et al.
Publicado: (2019)

The Dynamics of Naturally Acquired Immune Responses to Plasmodium falciparum Sexual Stage Antigens Pfs230 & Pfs48/45 in a Low Endemic Area in Tanzania
por: Bousema, Teun, et al.
Publicado: (2010)

Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment
por: Huang, Wei-Chiao, et al.
Publicado: (2020)

Antibody responses to two new Lactococcus lactis-produced recombinant Pfs48/45 and Pfs230 proteins increase with age in malaria patients living in the Central Region of Ghana
por: Acquah, Festus K., et al.
Publicado: (2017)

N-Terminal Pfs230 Domain Produced in Baculovirus as a Biological Active Transmission-Blocking Vaccine Candidate
por: Lee, Shwu-Maan, et al.
Publicado: (2017)

Elucidating functional epitopes within the N-terminal region of malaria transmission blocking vaccine antigen Pfs230
por: Miura, Kazutoyo, et al.
Publicado: (2022)

Profiling the Quality and Quantity of Naturally Induced Antibody Responses Against Pfs230 and Pfs48/45 Among Non-Febrile Children Living in Southern Ghana: A Longitudinal Study
por: Broni, Fermin K., et al.
Publicado: (2021)

Dynamics of anti-MSP3 and Pfs230 antibody responses and multiplicity of infection in asymptomatic children from southern Ghana
por: Amoah, Linda E., et al.
Publicado: (2018)

A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle
por: Salinas, Nichole D., et al.
Publicado: (2023)

Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate
por: Radtke, Andrea J., et al.
Publicado: (2017)

Potent transmission-blocking monoclonal antibodies from naturally exposed individuals target a conserved epitope on Plasmodium falciparum Pfs230
por: Ivanochko, Danton, et al.
Publicado: (2023)

Helminth-Induced Human Gastrointestinal Dysbiosis: a Systematic Review and Meta-Analysis Reveals Insights into Altered Taxon Diversity and Microbial Gradient Collapse
por: Kupritz, Jonah, et al.
Publicado: (2021)

A human antibody epitope map of the malaria vaccine antigen Pfs25
por: Shukla, Niharika, et al.
Publicado: (2023)

Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques
por: Scaria, Puthupparampil V., et al.
Publicado: (2021)

Phase 1 Trial of the Plasmodium falciparum Blood Stage Vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in Malaria Naïve Adults
por: Ellis, Ruth D., et al.
Publicado: (2010)

Design of a stabilized non-glycosylated Pfs48/45 antigen enables a potent malaria transmission-blocking nanoparticle vaccine
por: Dickey, Thayne H., et al.
Publicado: (2023)

Plant-produced transmission blocking Plasmodium falciparum Pfs25 subunit and VLP based vaccine candidates
por: Musivchuk, Konstantin, et al.
Publicado: (2012)

Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
por: Wu, Yimin, et al.
Publicado: (2008)

Phase 1 Study in Malaria Naïve Adults of BSAM2/Alhydrogel®+CPG 7909, a Blood Stage Vaccine against P. falciparum Malaria
por: Ellis, Ruth D., et al.
Publicado: (2012)

TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25
por: Thompson, Elizabeth A., et al.
Publicado: (2018)

Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer
por: Miura, Kazutoyo, et al.
Publicado: (2007)

Collective states in $^{230}$Ra fed by beta- decay of $^{230}$Fr
por: Kurcewicz, W, et al.
Publicado: (1986)

Antibody targeting of a specific region of Pfs47 blocks Plasmodium falciparum malaria transmission
por: Canepa, Gaspar E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p5sudr1k6vgfk1at8gib1lrecl